- Stocks
- Pharma & Healthcare
- Solara Active Pharma Sciences
Solara Active Pharma Sciences share price
NSE: SOLARAPharma & HealthcareDrug Manufacturers - Specialty & Generic
Solara Active Pharma Sciences at a glance
Solara Active Pharma Sciences (NSE: SOLARA) closed at ₹650.75 on 22 Oct 2026, up 1.48% on the day. With a market capitalisation of ₹3,140 Cr, it ranks 953rd by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Drug Manufacturers - Specialty & Generic.
Its return on equity was −0.6% in FY26. Over the past year the share price has risen 11.8%. Its 52-week range is ₹422.00 (30 Mar 2026) to ₹774.00 (15 Sep 2026); the last close is 15.9% below the high. Promoters held 41.93% of the company as of 30 Jun 2026; 37.11% of promoter shares were pledged.
Key numbers
- Market cap
- ₹3,140 CrRank 953 on NSE
- Price to book
- 1.51×FY26
- ROE
- −0.6%FY26
- ROCE
- 6.5%FY26
- Debt to equity
- 0.53FY26
- Net profit margin
- −0.5%FY26
- Book value / share
- ₹281.48FY26
- 52-week high
- ₹774.0015 Sep 2026
- 52-week low
- ₹422.0030 Mar 2026
- 1-year return
- +11.8%
- RSI (14-day)
- 45.5
Returns to 22 Oct 2026
| Period | 1 day | 1 week | 1 month | 3 months | 1 year |
|---|---|---|---|---|---|
| Price change | +1.48% | +1.7% | −13.3% | +21.2% | +11.8% |
Solara Active Pharma Sciences financials
| Item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| Revenue | ₹1,617 Cr | ₹1,268 Cr | ₹1,444 Cr | ₹1,289 Cr | ₹1,284 Cr | — |
| Operating profit | ₹222 Cr | −₹88 Cr | −₹45 Cr | −₹298 Cr | ₹1 Cr | — |
| Net profit | ₹221 Cr | −₹58 Cr | −₹22 Cr | −₹567 Cr | ₹1 Cr | — |
| EPS (₹) | ₹69.00 | −₹16.00 | −₹6.00 | −₹158.00 | ₹0.00 | — |
| Cash from operations | ₹155 Cr | −₹242 Cr | ₹156 Cr | ₹109 Cr | ₹213 Cr | — |
| Total debt | ₹155 Cr | ₹283 Cr | ₹235 Cr | ₹106 Cr | ₹114 Cr | ₹110 Cr |
| Shareholders' equity | ₹1,589 Cr | ₹1,525 Cr | ₹1,500 Cr | ₹934 Cr | ₹1,094 Cr | ₹1,253 Cr |
Solara Active Pharma Sciences shareholding pattern
| Holder | 30 Jun 2025 | 30 Sep 2025 | 31 Dec 2025 | 31 Mar 2026 | 15 May 2026 | 30 Jun 2026 |
|---|---|---|---|---|---|---|
| Promoters | 42.01% | 42.01% | 42.00% | 42.00% | 42.00% | 41.93% |
| Foreign institutions | 14.25% | 13.58% | 11.98% | 11.59% | 11.33% | 11.52% |
| Domestic institutions | 2.62% | 2.69% | 3.64% | 3.75% | 3.78% | 3.74% |
| Non-institutions | 41.11% | 41.72% | 42.37% | 42.66% | 42.89% | 42.81% |
| Promoter shares pledged | 38.95% | 35.32% | 26.04% | 31.57% | 36.57% | 37.11% |
Solara Active Pharma Sciences vs peers
The listed Pharma & Healthcare companies nearest to Solara Active Pharma Sciences by market capitalisation.
| Company | Price | 1 day | 1 year | Market cap | P/E | ROE |
|---|---|---|---|---|---|---|
| UNICHEMLABUnichem Laboratories | ₹495.95 | −3.51% | +5.5% | ₹3,492 Cr | 13.8 | — |
| AARTIDRUGSAarti Drugs | ₹381.15 | −1.51% | −24.5% | ₹3,479 Cr | 17.9 | — |
| SOLARASolara Active Pharma Sciences | ₹650.75 | +1.48% | +11.8% | ₹3,140 Cr | — | — |
| INDSWFTLABInd-Swift Laboratories | ₹347.05 | +1.92% | +240.9% | ₹3,018 Cr | 71.6 | — |
| ADVENZYMESAdvanced Enzyme Technologies | ₹265.45 | +1.39% | −13.2% | ₹2,972 Cr | 17.6 | — |
| SHUKRAPHARShukra Pharma | ₹63.62 | −7.18% | — | ₹2,797 Cr | 127.2 | — |
| DPC02Dishman Pharma | — | — | — | ₹2,676 Cr | — | — |
Ask anything about Solara Active Pharma Sciences
Pivot answers on the live chart with evidence you can check, and tests strategies against SOLARA's own history. Try: “Why has SOLARA moved over the last three months?” · “Backtest a 50-day moving-average crossover on SOLARA over five years” · “Compare SOLARA with UNICHEMLAB on margins and valuation”
Frequently asked questions about Solara Active Pharma Sciences
What is the share price of Solara Active Pharma Sciences today?
Solara Active Pharma Sciences (NSE: SOLARA) last closed at ₹650.75 on 22 Oct 2026. Its 52-week high is ₹774.00 and its 52-week low is ₹422.00.
What is the market cap of Solara Active Pharma Sciences?
Solara Active Pharma Sciences' market capitalisation is ₹3,140 Cr (₹3,140 Cr) at the 22 Oct 2026 close, ranking 953rd among the NSE companies Pivot tracks.
What is the ROE and ROCE of Solara Active Pharma Sciences?
Return on equity was −0.6% in FY26 and return on capital employed was 6.5% in FY26 (consolidated figures).
Is Solara Active Pharma Sciences a debt-free company?
No. Solara Active Pharma Sciences' debt-to-equity ratio was 0.53 in FY26, with total debt of ₹110 Cr.
How has Solara Active Pharma Sciences stock performed over the last year?
Solara Active Pharma Sciences' share price has risen 11.8% over the past year, +21.2% over three months and −13.3% over one month, to the 22 Oct 2026 close.
What is the shareholding pattern of Solara Active Pharma Sciences?
As of 30 Jun 2026: promoters 41.93%, foreign institutions 11.52%, domestic institutions 3.74%, non-institutions 42.81%. 37.11% of promoter shares were pledged.
Who are Solara Active Pharma Sciences' competitors?
The listed Pharma & Healthcare companies closest to Solara Active Pharma Sciences by market cap are Unichem Laboratories, Aarti Drugs, Ind-Swift Laboratories, Advanced Enzyme Technologies, Shukra Pharma and Dishman Pharma.
Is Solara Active Pharma Sciences a good stock to buy?
Pivot does not give buy or sell recommendations. This page sets out Solara Active Pharma Sciences' price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on SOLARA against its own history before risking money. This is analysis, not financial advice.
Sources and method
Prices: NSE daily closes to 22 Oct 2026 (returns and ratios at the 22 Oct 2026 close). Fundamentals: company filings via Moneycontrol, consolidated where available. Shareholding: exchange shareholding-pattern filings. The 52-week range uses intraday highs and lows; the chart marks closing prices. P/E is the last close over trailing twelve-month EPS. Market-cap rank is among the 4,183 NSE companies Pivot tracks; SEBI's bands call the top 100 large-cap and the next 150 mid-cap. Figures marked “—” are not available rather than zero. This is analysis, not financial advice.
More: all Pharma & Healthcare stocks · companies starting with S · all NSE stocks · this page as text